Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Inclusion Criteria, Exclusion Criteria, Dose Limiting Toxicity Criteria for First Cycle
Supplementary Methods from A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors | Synapse